Editor’s Briefing: October 5, 2026

In Short. Vaxcyte’s 31-strain pneumococcal vaccine met its main immune-response goals against the two leading adult shots in a 4,047-person phase 3 trial, Genentech licensed Alector’s brain-delivered enzyme for Parkinson’s disease for $100 million upfront, Genmab’s ovarian cancer drug held disease in check for a median 9.5 months, the medicine Nobel went to the discoverers of optogenetics, and the FDA let Alvotech double U.S. supply capacity for its Humira biosimilar.

---

Vaxcyte’s 31-strain vaccine clears its first pivotal test

Streptococcus pneumoniae causes pneumonia, meningitis and bloodstream infections, and it comes in dozens of strains called serotypes. A pneumococcal conjugate vaccine (PCV) trains the immune system against a fixed list of them. Vaxcyte’s VAX-31 covers 31. In OPUS-1, 4,047 U.S. adults got one dose of VAX-31, Pfizer’s Prevnar 20 (PCV20) or Merck’s Capvaxive (PCV21). In people 50 and older, all 28 serotypes shared with a comparator met the noninferiority test, meaning blood antibody activity one month later was not meaningfully lower. The three serotypes only VAX-31 covers, plus related serotype 20B, met superiority. Against PCV21 alone, serotypes 3 and 12F missed the stricter bar. Safety looked similar across vaccines. Two more phase 3 trials report in the first half of 2027, with an FDA filing planned for 2028. (Vaxcyte; Mugglehead)

Genentech licenses Alector’s brain-delivered Parkinson’s enzyme

Glucocerebrosidase, or GCase, is an enzyme that clears a fatty waste product inside cells. People with faulty copies of its gene, GBA, carry a higher risk of Parkinson’s disease and Lewy body dementia. Enzyme replacement therapy supplies working GCase by infusion, but large proteins rarely cross the blood-brain barrier. Alector’s AL050 attaches engineered GCase to the company’s Alector Brain Carrier, a shuttle built to ferry it into the brain. AL050 is still preclinical; in rodents and monkeys it increased brain GCase activity. Genentech takes worldwide rights and pays $100 million upfront, with up to $1.17 billion more in milestones plus royalties. Alector says the cash extends its runway into 2029 and keeps its brain-carrier platform for its own Alzheimer’s programs. (Alector / GlobeNewswire; SEC 8-K)

Genmab’s ovarian cancer conjugate posts durable responses

An antibody-drug conjugate (ADC) is an antibody that carries a toxic payload straight to cancer cells. Genmab’s rinatabart sesutecan (Rina-S) targets folate receptor α (FRα), a protein common on ovarian tumors. Platinum-resistant ovarian cancer is disease that returns soon after platinum chemotherapy. In 109 such patients, more than half on their fourth or fifth line of therapy, 45.9% had confirmed tumor shrinkage, responses lasted a median 12.1 months, and the median stretch without the cancer worsening was 9.5 months. The study had no control arm. Activity appeared in patients with little of the target protein and in those already given AbbVie’s Elahere, a rival ADC. A randomized phase 3 is running. (Genmab / GlobeNewswire; Fierce Biotech)

Optogenetics wins the Nobel Prize in medicine

Optogenetics lets scientists switch chosen nerve cells on or off with light. Peter Hegemann and Georg Nagel found channelrhodopsin, a light-sensitive protein that helps a single-celled alga swim toward light, and showed it worked in other cells. Karl Deisseroth put its gene into rat neurons and fired them with blue light inside a living brain. The Karolinska Institutet gave the three the 2026 Nobel Prize in Physiology or Medicine on Monday. The method is now standard for linking specific neurons to memory and behavior, and it is being studied as a treatment. The winners share about $1.2 million. (STAT)

FDA lets Alvotech double U.S. capacity for its Humira copy

A biosimilar is a near-identical copy of a biologic drug whose patents have expired. Alvotech’s Simlandi (adalimumab-ryvk) copies AbbVie’s Humira and is sold in the United States with Teva. The FDA approved a second production suite at Alvotech’s Reykjavik plant for the drug’s active ingredient, which the company says doubles the capacity available for U.S. supply. Alvotech said the approval also confirms that earlier inspection problems at the site are resolved, after the FDA closed its July inspection with a Voluntary Action Indicated rating. Pending applications for copies of Simponi, Eylea and Prolia still face their own reviews. (Alvotech / GlobeNewswire)

What to watch

pdufa.bio lists Roche’s Tecentriq for stage III colon cancer after surgery on October 9, Roche’s Enspryng in thyroid eye disease on October 15, and Viatris’s phentolamine eye drops on October 17. GSK’s hepatitis B drug bepirovirsen follows on October 26.